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Disruption of cellular adhesion is an essential pathobiologic step leading to tumor dissemination. Mucin 1
(MUC1) is a mucinous glycoprotein expressed at the surfaces of epithelial cells in many tissues and their
carcinomas. MUC1 plays crucial roles in tumor invasion and metastasis, especially in opposing cell adhesion.
We have shown that virus infection, specifically by the human tumor virus Epstein-Barr virus (EBV) induces
a spectrum of cellular invasiveness and metastasis factors. Here we show that expression of MUC1 is increased
in diverse latently EBV-infected cell lines that express latent membrane protein 1 (LMP1), the main viral
oncoprotein, and that the level of MUC1 was suppressed by expression of a dominant-negative mutant of
LMP1. Expression of LMP1 in EBV-negative nasopharyngeal cell lines induces expression of MUC1 through
activation of the MUC1 promoter via binding of STAT1 and STAT3. Finally, LMP1 reduces cell adhesion
ability, which is restored by inhibition of MUC1 expression with MUC1 small interfering RNA (siRNA). In
addition, LMP1 increases cell invasiveness, which is suppressed by MUC1 siRNA. Thus, LMP1 induces MUC1,
a factor important in an early step of detachment and release of tumor cells, which along with induction of
other invasiveness and angiogenic factors may combine to act in a complex sequential process that culminates
in metastasis of EBV-infected tumor cells.
The close association of Epstein-Barr virus (EBV) with several
invasive malignancies, especially nasopharyngeal carcinoma
(NPC), B-cell lymphoproliferative diseases, Hodgkin’s disease,
and some invasive breast cancers (5, 33), has raised the question
of whether a tumor virus could contribute to the invasive charac-
ter of tumors. Invasion into surrounding tissue is a characteristic
of malignant tumors—strikingly so in the case of NPC, which is
closely linked to EBV infection. Both invasion and metastasis are
programmed through sequential multistep pathobiologic pro-
cesses characterized by disruption of many aspects of normal cell
behavior. In papers beginning in 1998 (for a review, see reference
54), we have reported that latent membrane protein 1 (LMP1)
induces the expression of a series of cellular invasion and metas-
tasis factors, such as matrix metalloproteinase 9 (MMP9), which
plays a critical role in the invasion of the basement membrane
(30, 44, 53). LMP-1 also induces the MMP-1 promoter (22).
Furthermore, MMP9 is involved in production of vascular endo-
thelial factor (VEGF) (4). In addition, LMP1 induces angiogenic
factors, such as VEGF through induction of cyclooxygenase 2
(COX-2) and hypoxia-inducible factor 1 (HIF-1) (23, 31, 50).
Moreover, LMP1 induces and causes release of fibroblast growth
factor 2 (FGF-2) into extracellular fluid (49; S. Ceccarelli, V.
Visco, N. Wakisaka, J. S. Pagano, and M. R. Torrisi, submitted for
publication). LMP1 expression also promotes cell migration and
invasive growth via Ets-1 expression (19, 21).
In most EBV-associated tumors, infection is predominantly
latent. The EBV genes expressed in latent infection are re-
stricted to six EBV nuclear antigens (EBNA-1, -2, -3A, -3B,
-3C, and -LP), three latent membrane proteins (LMP1, -2A,
and -2B), and two small nonpolyadenylated RNAs (EBER1
and -2). The patterns of expression of the genes that encode
these proteins determine latency type. In type I latency, such as
Burkitt’s lymphoma, only EBNA1, EBERs, and sometimes
LMP2A are expressed. In type II latency, such as NPC and
Hodgkin’s disease, EBNA1 and the three latent membrane
proteins are expressed. In type III latency, typified by EBV
lymphoproliferative disease, all of the EBNAs and LMPs are
expressed (33). LMP1 is considered the principal EBV onco-
gene and can produce lymphomas in transgenic mice (25). The
carboxyl-terminal portion of LMP1 in the cytoplasmic domain
of the protein contains two functional signaling regions:
COOH-terminal activation region 1 (CTAR1) and CTAR2.
Both activate nuclear factor B (NF-B) (20, 44).
In addition, there is a Janus kinase 3 (JAK3) activation and
binding domain positioned between CTAR1 and CTAR2 that
results in activation of signal transducer and activator of transcrip-
tion 1 (STAT1) and STAT3 in fibroblasts (15). STATs are latent
transcription factors that become activated by phosphorylation on
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a single tyrosine, typically in response to extracellular ligands (9,
42). Various cytokines and growth factors can cause STAT phos-
phorylation through receptor or associated kinases. Once phos-
phorylated, STATs can form homo- or heterodimers that accu-
mulate in the nucleus, recognize specific DNA sequences, and
activate transcription of target genes (9, 42). However, the pattern
of activation of STATs by LMP1 is unclear, perhaps because it is
influenced by cell type (7, 55). Chen et al. reported that adherent
cell lines stably transfected with LMP1 induced tyrosine-phos-
phorylated STAT3 and -5, but not STAT1 (7). On the other hand,
in suspension cell lines, Zhang et al. showed that LMP1 can
induce expression of STAT1 protein as well as serine but not
tyrosine phosphorylation of the protein (55). LMP1 also induced
expression of STAT2 and -3 proteins (55).
A series of reports have built a picture of how a tumor virus
may have a major impact on invasion and metastasis. This process
also requires an earlier step that involves antiadhesive functions,
such as dissociation of cell-cell and cell-matrix adhesion, which we
now address. The main regulator of the cell adhesion system is
E-cadherin. Epithelial E-cadherin, a component of adherens
junctions, is crucial for the organization and maintenance of dif-
ferentiated epithelia (17). This protein mediates cell adhesion via
a homophilic and Ca2-dependent pathway. In cancer, the main-
tenance and integrity of epithelia are lost, and the resulting dis-
sociation of cells leads ultimately to metastatic dissemination.
Dissociation of cells can occur through a decrease in the local
expression level of E-cadherin. It is well documented that LMP1
downregulates E-cadherin gene expression through cellular DNA
methylation machinery by activation of DNA methyltransferase
(48). However, the mechanism of antiadhesion is otherwise un-
clear except for E-cadherin itself. The E-cadherin-mediated cell
adhesion system is modulated by the mucin-like glycoprotein
MUC1, one of the mucin protein families. In breast cancer cells,
the cytoplasmic domain of MUC1 binds -catenin, leading to a
decrease of E-cadherin–-catenin complex and resulting in an
antiadhesive effect (27).
MUC1 is a large surface glycoprotein expressed by epithelial
cells that is overexpressed and aberrantly glycosylated in several
carcinomas, such as breast cancer (13, 46, 47). The biological
functions of MUC1 are inferred from in vitro experiments (38,
47). The long and rigid extracellular domain of MUC1 can shield
adhesion molecules and diminish cellular adhesion if the glyco-
protein is present at a high enough density on the cell surface. In
addition, MUC1 represses T-cell proliferation, resulting in immu-
nosuppressive effects (14). Recent papers indicate that MUC1 is
regulated by cytokines that signal through NF-B, STAT1, and
STAT3 (12, 26). In addition, because MUC1 may be an optimal
candidate for active immunotherapy (1), specifically as a target
for dendritic cell therapy and vaccination for MUC1-positive can-
cers, it has increasing potential medical importance.
Here, we show the first evidence that the EBV oncoprotein
LMP1 induces MUC1 expression. We demonstrate that LMP1
activates STAT1 and STAT3, which in turn results in induction
of MUC1, and finally enhances dissociation of adherent cells
and cell invasiveness.
MATERIALS AND METHODS
Cell culture. KH-1 and KH-2 lines are EBV-positive type II cell lines derived
from fusion of KR-4 (an EBV-positive type III lymphoblastoid cell line) and
HeLa cells (human cervical carcinoma) (gifts of Maria Masucci, Karolinska
Institute, Stockholm, Sweden) (8). Ad-AH cells, provided by Erik K. Flemington
(Tulane University, New Orleans, LA), are an EBV-negative human nasopharyn-
geal cell line (45). T-47D (a human breast cancer cell line) and HeLa cells were
obtained from the American Type Culture Collection. MDA-MB-231 (a human
breast cancer cell line) and EBV-infected MDA-MB-231 clones (C4A3, C1D12,
C2G6, and C3B4) were described previously (3, 50). The parental MDA-MB-231
cells and C4A3 clone are LMP1-negative cells. C1D12, C2G6, and C3B4 are
LMP1-positive clones. LMP1 expression is strongest in the C3B4 clone and not
detected in C4A3. MDA-MB-231 cells were maintained in RPMI 1640, with 10%
fetal bovine serum (FBS), 4 M L-glutamine, penicillin, and streptomycin. EBV-
infected MDA-MB-231 clones were maintained in the same medium, but with
700 g/ml G418 (Life Technologies, Grand Island, NY). The other cells were
maintained in Dulbecco’s modified Eagle’s medium with 10% FBS and penicillin
and streptomycin.
Antibodies and reagents. Mouse LMP1 monoclonal antibody was purchased
from DAKO (Glostrup, Denmark). Mouse MUC-1 monoclonal antibody, clone
VU2G7 was from Chemicon International Inc. (Temecula, CA). Mouse mono-
clonal antibody against STAT1, STAT3, tyrosine-phosphorylated STAT1 (pY-
STAT1) (phosphorylated tyrosine at position 701 [pY-701]), and pY-STAT3
(pY-705) were from Transduction Laboratories (San Diego, CA). Mouse mono-
clonal antibody against -tubulin was from Sigma (St. Louis, MO). Mouse mono-
clonal hemagglutinin antibody and rabbit polyclonal histone antibody (H2B)
were from Santa Cruz Biotechnology (Santa Cruz, CA). Collagen type I gelatin,
laminin, and fibronectin, were purchased from Sigma. Recombinant interleukin
6 (IL-6) was from R & D Systems (Minneapolis, MN). MUC1 siRNA was
purchased from Dharmacon (Chicago, IL).
Plasmids and site-directed mutagenesis. pcDNA3-based LMP1 has been de-
scribed elsewhere (53). LMP1-DM, which is doubly mutated in both the CTAR1
and CTAR2 regions and acts as an LMP1 dominant-negative mutant, has been
described elsewhere (56). To monitor expression of LMP1-DM, we used West-
ern blots with LMP1 antibodies. Hemagglutinin-tagged STAT1 dominant-nega-
tive and STAT3 dominant-negative (STAT1-DN and STAT3-DN) mutants were
generous gifts from Toshio Hirano (Osaka University, Osaka, Japan) (32).
cDNA of the tandem repeat domain of the MUC1 gene in Bluescript vector for
Northern analysis was the generous gift from Joyce Taylor-Papadimitriou (Im-
perial Cancer Research Fund, London, United Kingdom) (24).
Transient and stable transfection. Cells were transfected with 1 g of appro-
priate plasmid(s) with the use of Effectene transfection reagent (QIAGEN,
Valencia, CA) following the manufacturer’s instructions. Stable cell lines were
established by cultivating Ad-AH cells in the presence of 800 g/ml G418. For
siRNA transfection, stable Ad-AH cell lines with or without pcLMP1 were
transfected with the use of Lipofectamine 2000 transfection reagent (Invitrogen,
Carlsbad, CA).
Western blot analysis. Transfected cells were cultured in appropriate medium
with 10% FBS for 2 days and then cultured in appropriate medium without FBS
for 24 h. Whole-cell lysates were analyzed by Western blotting as described
previously (50). Nuclear extracts were prepared by NE-PER nuclear and cyto-
plasmic extraction reagents according to the manufacturer’s protocol (Pierce,
Rockford, IL).
Northern blot analysis. RNA preparation and Northern analysis were carried
out as described previously (24, 51).
Electrophoretic mobility shift assay (EMSA). Nuclear extracts were prepared
from pcDNA3- or pcLMP1-transfected (transiently transfected) Ad-AH cells as
described previously (50). The following double-stranded 32P-labeled oligonu-
cleotide probes were synthesized: wild-type STAT-MUC1 oligonucleotide, 5-G
GCTATTCCGGGAAGTGGT-3; mutant STAT-MUC1 oligonucleotide, 5-G
GCTACTCGAGAAGTGGT-3 (12). For reaction, equal amounts of nuclear
extract (15 g) were incubated in DNA-binding buffer as described elsewhere
(12). Samples were loaded on 5% native polyacrylamide gels in a ice-cold 0.5
Tris-borate EDTA (TBE) buffer. Gels were vacuum dried and exposed for
autoradiography. For competition assays, excess amounts of wild-type or mutant
cold oligonucleotides were used (100). For supershift assays, we used antibod-
ies against STAT1 and STAT3 as described earlier (12).
In vitro cell invasiveness assay. Invasiveness assays were performed with
the use of Biocoat Matrigel invasion chambers (Becton Dickinson Labware,
Bedford, MA) as described previously (30). Biocoat cell culture inserts were
used for uncoated assays. Stably pcLMP1-transfected Ad-AH cells and stably
pcDNA3-transfected Ad-AH cells were transfected with either control
siRNA or MUC1 siRNA and cultivated for 48 h for the assays which were
done in triplicate.
Cell adhesion assay. The cell adhesion assay was based on an established
method (38). Briefly, microwells were coated with type I collagen, gelatin, lami-
nin, or fibronectin (10 g/cm2) overnight at 4°C and then washed once with a
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phosphate-buffered saline solution. Bovine serum albumin (1.5%) was added to
the coated wells and incubated for 1 h at 37°C to block the remaining binding
sites. Triplicate suspended aliquots of stably pcLMP1-transfected Ad-AH cells
and control cells transfected with either control siRNA or MUC1 siRNA and
cultivated for 48 h were added to each coated well and allowed to incubate for
1 h at 37°C. After the wells were washed three times with a phosphate-buffered
saline solution, adherent cells were stained with 0.04% crystal violet solution.
The crystal violet was solubilized by 50% methanol and 0.1% Triton X-100
FIG. 1. Levels of MUC1 protein are increased in LMP1-expressing type II latently EBV-infected cells and are induced by LMP1. (A) KH-1
and KH-2 are type II cell lines derived by fusion of KR-4 and adherent HeLa cells (8); HeLa cells are used as a negative control. Subconfluent
cells were lysed for Western blots. Half of the protein from T47-D cells treated with IL-6 was used as a positive control (12). (B) MDA-MB-231
is an EBV-negative human breast carcinoma cell line. C1D12, C2G6, and C3B4 are its EBV-infected derivatives that express LMP1. (C) Sup-
pression of LMP1 in type II latently infected cells resulted in suppression of expression of MUC1. An LMP1 dominant-negative mutant
(LMP1-DM) was transfected into C3B4 cells; MDA-MB-231 is used as a negative control. Expression of LMP1-DM was confirmed by Western
blotting with LMP1 antibody. (D) LMP1 induces expression of MUC1 protein. Lysates from Ad-AH or T47-D cells transiently transfected with
either pcDNA3 or pcLMP1 expression plasmids were used, as well as Ad-AH cells stably transfected with either pcDNA3 (pcDNA3-AdAH) or
pcLMP1 (pcLMP1-AdAH). MUC1 has an apparent molecular mass of more than 400 kDa. Brackets indicate the two major mature allelic forms
of MUC1. (E) Induction of MUC1 by LMP1 is at the transcriptional level. RNA from Ad-AH cells transfected with either pcDNA3 or pcLMP1
expression plasmid was used. RNA was analyzed by Northern blotting for MUC1 tandem repeat; 28S rRNA was used as a loading control.
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(Sigma). Finally, absorbance was measured at 590 nm. Results were expressed as
a percentage of the initial number of cells.
Statistical analysis. Significant differences were determined by the paired t
test. A P value of 	0.05 was considered statistically significant.
RESULTS
The level of MUC1 protein is increased in latently infected
type II adherent cells. We first determined endogenous levels
of MUC1 in EBV-infected cell lines. Type II latently infected
cells express EBNA1 and latent membrane proteins (33).
KH-1 and KH-2 are type II adherent cell lines derived by
fusion of an EBV-infected lymphoblastoid suspension cell line,
KR-4, and adherent HeLa cells (8). The expression level of
MUC1 protein is clearly greater in KH-1 and KH-2 cells, which
express EBV latency proteins, including LMP1, than in HeLa
cells (Fig. 1A). EBV-negative T47-D cells treated with IL-6
were used as a positive control for expression of MUC1 (12).
MUC1 has two allelic mature forms with an apparent molec-
ular mass of more than 400 kDa (12, 26).
MDA-MB-231 is an EBV-negative breast cancer cell line,
and C4A3, C1D12, C2G6, and C3B4 are EBV-infected clones
derived from it. As shown in Fig. 1B, the MUC1 level is
increased in the LMP1-positive clones, C1D12, C2G6, and
C3B4, that express LMP1, but not in LMP1-negative C4A3
cells or in the parental line, MDA-MB-231. Beads migrating
with LMP1 in the first two lanes of Fig. 1B are nonspecific.
We then examined whether the increase in the level of
MUC1 in type II latently cells is due to LMP1. LMP1-DM
expression plasmid was transfected into the C3B4 cell line,
which expresses both LMP1 and MUC1 at high levels.
LMP1-DM suppressed expression of MUC1 as shown in Fig.
1C. The level of suppression correlated with the amount of
LMP1 dominant-negative mutant used.
Thus, the level of MUC1 protein corresponds to the level of
LMP1 in the two quite different sets of cell lines. These results
prompted investigation of the role of LMP1 in the induction of
MUC1 protein.
LMP1 induces expression of MUC1 protein and mRNA.
Ad-AH is an EBV-negative nasopharyngeal epithelial cell line.
Stable or transient transfectants of Ad-AH cells expressing
LMP1 and controls were lysed for analysis by Western blotting.
The expression level of MUC1 was significantly higher in
LMP1-expressing cells whether stably or transiently trans-
fected than in those cells not expressing the viral protein (Fig.
1D). We also detected a higher level of MUC1 in the LMP1-
transfected T47-D breast carcinoma cells than in pcDNA3-
transfected T47-D cells (Fig. 1D).
Next, we investigated whether LMP1 induces transcription
of MUC1. As shown in Fig. 1E, LMP1-transfected Ad-AH
cells had higher levels of MUC1 RNA than the control cells
did. Whether induction of MUC1 by LMP1 is direct or indirect
remains to be ascertained.
LMP1-induced activated STAT1 and STAT3 are required
for induction of MUC1. Whether LMP1 can induce tyrosine-
phosphorylated STAT1 is uncertain (7, 15, 55). The effects of
activated STAT1 and -3 are critical for MUC1 transcription
(12). First, we examined whether LMP1 can induce activated
STAT1 and -3, i.e., their tyrosine-phosphorylated forms. Using
recently developed monoclonal antibodies, we detected acti-
vated STAT1 and -3 in whole-cell lysates and nuclear extracts
of Ad-AH cells expressing LMP1 (Fig. 2A and B). In addition
to these results, LMP1 expression increases the level of STAT1
itself. Next we examined the effects of STAT1-DN and
STAT3-DN mutants on the levels of MUC1 induced by LMP1.
Cotransfection of STAT1-DN mutants with LMP1 repressed
induction of MUC1 by LMP1 (Fig. 2C). Similarly, STAT3-DN
suppressed MUC1 expression by LMP1 (Fig. 2D). Thus,
STAT1 and -3 signaling appears to affect expression of MUC1
induction by LMP1.
Gamma interferon together with tumor necrosis factor alpha
stimulates expression of MUC1 (26). However, with LMP1 as
the inducing factor, we did not detect a consistent effect on
MUC1 by cotransfection of the IB superrepressor srIB
(S32A S36A) with the viral protein (30, 35; data not shown).
LMP1 induces binding activities of STATs for the MUC1
promoter. We confirmed whether the LMP1-inducible factors
STAT1 and STAT3 can bind to a target sequence in the MUC1
promoter by an EMSA. When oligonucleotide probes containing
STAT-binding sites (Fig. 3A) from the MUC1 promoter were
incubated with nuclear extracts from Ad-AH cells transiently
transfected with or without LMP1, binding of complexes contain-
ing STAT (Fig. 3A) was detected clearly in the LMP1-expressing
cells. An excess amount of unlabeled oligonucleotides with wild-
type sequence competed with the probe for binding, whereas
oligonucleotides with mutated sequence did not.
Next since a previous report showed that both STAT1 and
STAT3 are required for complex formation on the STAT
DNA-binding site, we tested for changes in migration or de-
tection of STAT1- and STAT3-containing binding complexes
that could be produced by STAT antibodies. STAT1 antibody
produced a supershifted band, whereas STAT3 antibody dis-
rupted the protein-DNA binding complex (Fig. 3B). These
results suggest that both STAT1 and -3 can bind in a complex
to the same STAT-specific sequences in the MUC1 promoter.
LMP1 enhances matrix-cell dissociation. To examine
whether adhesion of cells is affected in cells that express
LMP1, we used a cell-matrix adhesion assay. First, to repress
expression of MUC1, we transfected MUC1 siRNA into stably
pcLMP1 or pcDNA3-transfected Ad-AH cells. Figure 4A
shows that MUC1 siRNA completely abolished expression of
both endogenous and LMP1-induced MUC1 protein. The
same samples were used to appraise the effects of LMP1 and
MUC1 siRNA on cell adhesion in the matrix adhesion assays.
As shown in Fig. 4B, LMP1-expressing Ad-AH cells lost their
ability to bind to main components of matrix (collagen type I,
gelatin, laminin, and fibronectin) to a significant extent even
though the binding rates are different for each matrix (Fig. 4B,
P 	 0.05). However, by use of MUC1 siRNA to inhibit MUC1
expression, the antiadhesive effect was reversed, and cell ad-
hesion was restored except with fibronectin (P 	 0.05). Trans-
fection of MUC1 siRNA into pcDNA3-transfected cells did
not affect binding significantly (see the leftmost two bars for
each matrix component in Fig. 4B). Thus, expression of MUC1
induced by LMP1 appears to be required for the antiadhesive
function of LMP1-expressing cells.
LMP1 induces cell invasiveness via MUC1. We have shown
that LMP1-induced MMP9 enhances invasiveness of LMP1-ex-
pressing adherent cells in vitro (30). There are also reports of cell
invasiveness related to expression of MUC1 in in vitro invasion
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assays (38). A Matrigel invasion chamber system is commonly
used to assay tumor cell invasiveness in vitro (30, 38). LMP1-
expressing Ad-AH cells were more than twice as invasive in this
assay compared with pcDNA3-transfected Ad-AH cells (Fig. 4C).
The results were statistically significant (P 	 0.05), suggesting that
LMP1 is a possible invasiveness-inducing factor in these cells.
However, since several reports have shown that MUC1 itself also
contributes to cell invasiveness, we examined the contribution of
MUC1 induced by LMP1 to this property. With the use of MUC1
siRNA, we showed that LMP1-induced invasiveness could be
clearly inhibited (compare the two rightmost bars in Fig. 4C). The
results suggest that LMP1 also contributes to cell invasiveness
through induction of MUC1.
DISCUSSION
LMP1 expression is not only essential for B-cell immortal-
ization by EBV, but it is the only EBV protein that transforms
FIG. 2. Activated STAT1 and STAT3 are required for the induction of MUC1. (A) LMP1 induces tyrosine-phosphorylated STAT1 and STAT3
(pY-STAT1 and pY-STAT3) in whole-cell lysates of Ad-AH cells. (B) LMP1 induces tyrosine-phosphorylated STAT1 and STAT3 (pY-STAT1 and
pY-STAT3) in nuclear extracts of Ad-AH cells. Histone H2B was used as a loading control. (C) Ad-AH cells were transfected with pcDNA3 or
pcLMP1, or pcLMP1 plus STAT1-dominant-negative (DN) mutant. Cell lysates were used for Western blotting. HA, hemagglutinin. (D) Ad-AH
cells were transfected with pcDNA3 or pcLMP1 with or without STAT3-DN. Cell lysates were used for Western blotting.
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nonlymphoid cells, such as rodent fibroblasts (20), human ep-
ithelial cells (10), and human keratinocytes (11). Conse-
quently, the primary oncogenic properties of LMP1 have been
the focus of innumerable investigations. Here we continue our
investigations of another aspect of LMP1 function, namely, its
ability ultimately to affect tumor progression. NPC is a highly
invasive malignancy, and LMP1 is expressed in at least 70% of
NPCs and in all EBV preinvasive NPC lesions (34). We have
presented varied and mounting evidence that LMP1 promotes
cell invasion and metastasis as well as angiogenesis (23, 30, 31,
44, 49, 50, 53, 54). However, tumor invasion and metastasis
also require counteraction of cell-adhesive functions.
The extracellular mucin-like domain of MUC1 can shield
adhesion molecules and diminish cellular adhesion (13, 52).
Overexpression of MUC1 in carcinoma cells (18) is expected to
have an effect on cellular behavior similar to that of loss of
function of the major epithelial adhesion molecule E-cadherin,
which has been shown recently to promote invasion and me-
tastasis of carcinoma cells (48). Overexpression of MUC1 in
several cancers is reported to correlate with poor prognosis
(16). MUC1 has been used as an antigen for detection of
recurrence of breast cancer, and detection of MUC1 mRNA
may be useful as a marker for metastasis of gastric cancer
(2). In addition, MUC1 is widely considered one of the most
promising candidates for immunization against several can-
cers (6). In this paper, we demonstrate that LMP1 activates
STAT1 and STAT3, resulting in expression of MUC1, and
that inhibition of expression of these factors inhibits expres-
sion of MUC1 by LMP1 at the protein and transcriptional
levels.
The first report concerning induction of STATs by LMP1
showed that the viral protein increases DNA-binding activities
for STAT1 and STAT3 in fibroblasts detected by an EMSA
(15). Chen et al. showed that LMP1 induces activated STAT3
and STAT5 in adherent cell lines, but not STAT1 (7). A sub-
sequent report by Zhang et al. revealed that LMP1 induced
increases in the total amount of STAT1, but not the tyrosine-
phosphorylated form, in suspension cell lines (56). However, in
our system, LMP1 induces activated STAT1 and -3, as well as
increases in the total amount of STAT1 in Ad-AH cell lines
consistent with the first report in this field (15). Moreover, the
EMSA results showing that LMP1 can induce both activated
STAT1 and -3 support results shown by Western blotting. We
conclude that although whether LMP1 activates STAT1 is still
controversial to some extent, the differences observed may be
attributed to the different cell lines used or to experimental
FIG. 3. LMP1 induces binding of nuclear factor to STAT1 and STAT3 sequences in the MUC1 promoter. (A) Induction of nuclear factor
binding to the STAT sequence. Nuclear extracts (NE) from Ad-AH cells were mixed with 32P-labeled STAT probe and analyzed by EMSAs.
Nonlabeled STAT (wild type [Wt], 100) or mutated (Mt) probe were used as competitors. (B) Identification of STAT complexes. Nuclear extracts
(NE) were incubated with antibodies specific for STAT1 (STAT1) or STAT3, and complexes were resolved by EMSAs. The arrow indicates a
band supershifted by STAT1 antibody. Binding of STAT3 is attenuated by a STAT3 antibody. NS, nonspecific binding.
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FIG. 4. LMP1-induced MUC1 reduces cell adhesion to extracellular
matrix and enhances cell invasiveness in vitro. (A) Stably pcDNA3- or
pcLMP1-transfected Ad-AH cells with or without MUC1 siRNA (100
nM) were analyzed for MUC-1 by Western blotting. (B) Cell binding to
matrix and inhibition by MUC1 siRNA indicated by the percentage of
Ad-AH cells initially added. Data were calculated as the means of three
replicate samples plus standard deviations (error bars). Values that were
significantly different from each other (P 	 0.05) are indicated (*). N.S.,
not significantly different. (C) Increase in invasiveness of Ad-AH cells
produced by LMP1 in Matrigel assays is inhibited by MUC1 siRNA. The
invasion index is calculated as described previously (29). Values are shown
as averages plus standard deviations (error bars) from triplicate experi-
ments. Ad-AH cells were stably transfected with pcDNA3 or pcLMP1.
Values that were significantly different from each other (P 	 0.05) are
indicated (*).
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parameters, such as specificity of antibodies, LMP1 constructs,
and transfection methods.
A recent report shows that activated STAT1 and STAT3 are
critical for MUC1 transcription (12). STAT1-DN and STAT3-
DN inhibited LMP1-induced MUC1 at the protein level (Fig. 2C
and D). We confirmed these results by showing that both STAT1
and STAT3 could bind to the MUC1 promoter construct in cells
in which LMP1 has expressed (Fig. 3A). We also found that
LMP1-induced STAT1 and -3 could bind in a complex to the
MUC1 promoter by supershift complex analyses (Fig. 3B).
In the last part of the study, we examined whether LMP1-
induced MUC1 has potential biological significance through
the use of cell adhesion and in vitro invasion assays. First, we
showed that LMP1-expressing cells reduce the ability of cells to
adhere to the main components of matrix. MUC1 siRNA re-
stored the ability to bind to several matrices except for fi-
bronectin. A recent paper revealed that MUC1 does not affect
binding activity to fibronectin (38). At this point, we conclude
that even though LMP1 reduces cell-binding activity to fi-
bronectin, this property may be affected by unknown LMP1-
inducible factors, not by MUC1. That LMP1 reduces cell ad-
hesion functions and that this reduction may be caused by
MUC1 provide the first such evidence in this field.
Since MUC1 expression may induce cell invasiveness by
interacting with E-cadherin or -catenin (43, 47), with the use
of MUC1 siRNA, we showed that LMP1-induced cell invasive-
ness could be repressed by reducing expression of MUC1. The
results suggest that at least MUC1 induced by LMP1 is re-
quired for this phenomenon. Thus, LMP1-induced MUC1 af-
fects cell invasiveness and dissociation of adherent cells. LMP1
can also induce cell invasiveness via induction of MMP9 (30).
Recently, MUC1 has gained attention in another sphere, as
a number of proto-oncogenes that interact with MUC1, such as
epidermal growth factor receptor (EGFR), c-Src, and -cate-
nin, have been identified (27, 28, 43). In vitro studies show that
defined sequence in the cytoplasmic domain of MUC1 inter-
acts with -catenin and can compete with E-cadherin at ad-
herens junctions for binding of -catenin when expressed at
high levels. On the other hand, c-Src and EGFR phosphorylate
MUC1, and these events promote interactions between -cate-
nin and MUC1 (28, 41). Interestingly, LMP1 induces EGFR in
adherent cell lines (29), which may promote formation of
MUC1–-catenin complexes. Also, in other work we have
shown that type III latently infected lymphocytes express high
levels of -catenin (39, 40), which may also contribute to for-
mation of these complexes.
This study is the first to show that LMP1 induces MUC1
expression by STAT1 and STAT3 signaling. Furthermore, we
detected activated STAT1 at the protein level, and these in-
teractions including STAT1 and STAT3 may enhance MUC1
expression. Finally, we found that MUC1 induction by LMP1
affects cellular invasive and antiadhesive functions. Thus,
LMP1 induces key factors required in the multistep process of
invasion and metastasis: destruction of basement membrane,
angiogenesis, cell motility (19, 21, 23, 30, 31, 44, 49, 50, 53, 54),
and now a newly identified factor, cell adhesion capacity. EBV
is the first tumor virus shown to induce this array of factors
crucial in late stages of oncogenesis, adding significantly to its
oncogenic properties (54).
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